Created in 2010 (France), TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly own 306 sister brands and 4959 competing brands. The TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly brand is owned by Ipsen, a company listed in Paris. The International Securities Identification Number (ISIN) of Ipsen is FR0010259150. TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly belongs to the Drug Manufacturers business sector.

TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly is a brand of Ipsen (IPN) News

International deposit : 2010 Business sector Drug Manufacturers

All news Marketscreener Logo
Ipsen (TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly)

loader
Stock exchange: More information on Ipsen (TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly) Marketscreener Logo